Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, announced that its Cu-64 SAR-bis PSMA clinical trial in patients with confirmed prostate cancer is open for recruitment at two sites, Genesis Care CTA Medical Clinic, Perth and Nepean Hospital, Sydney.

Clarity’s Executive Chairman, Dr. Alan Taylor, commented, “We are very excited to open this trial for patients with newly diagnosed prostate cancer using our optimized PSMA agent, Cu-64 SAR-bis PSMA, that has the novel combination of two targeting agents attached to our SAR Technology.”

The PROPELLER trial is a Phase I Positron Emission Tomography (PET) imaging trial of participants with confirmed prostate cancer using Cu-64 SAR-bis PSMA. It is a 30-patient clinical trial conducted across three sites in Australia (NCT04839367)

To read more please visit:

https://www.claritypharmaceuticals.com/news/propeller_open/

Source: CLARIRY PHARMACEUTICALS